VolitionRX Limited (VNRX): Price and Financial Metrics

VolitionRX Limited (VNRX): $0.70

0.02 (-3.29%)

POWR Rating

Component Grades








VNRX Price/Volume Stats

Current price $0.70 52-week high $2.74
Prev. close $0.73 52-week low $0.63
Day low $0.68 Volume 163,349
Day high $0.73 Avg. volume 147,116
50-day MA $1.15 Dividend yield N/A
200-day MA $1.68 Market Cap 55.05M

VNRX Stock Price Chart Interactive Chart >


  • VNRX scores best on the Sentiment dimension, with a Sentiment rank ahead of 66.1% of US stocks.
  • The strongest trend for VNRX is in Quality, which has been heading down over the past 177 days.
  • VNRX's current lowest rank is in the Value metric (where it is better than 6.45% of US stocks).

VNRX Stock Summary

  • With a price/sales ratio of 104.42, VOLITIONRX LTD has a higher such ratio than 97.96% of stocks in our set.
  • VNRX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 97.49% of US stocks.
  • As for revenue growth, note that VNRX's revenue has grown 167.73% over the past 12 months; that beats the revenue growth of 96.44% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to VOLITIONRX LTD, a group of peers worth examining would be LUMO, TVTX, APM, FBIO, and CASA.
  • VNRX's SEC filings can be seen here. And to visit VOLITIONRX LTD's official web site, go to www.volition.com.

VNRX Valuation Summary

  • In comparison to the median Healthcare stock, VNRX's price/sales ratio is 5384.21% higher, now standing at 104.2.
  • Over the past 141 months, VNRX's EV/EBIT ratio has gone up 1883.4.

Below are key valuation metrics over time for VNRX.

Stock Date P/S P/B P/E EV/EBIT
VNRX 2023-09-22 104.2 9.3 -1.6 -1.2
VNRX 2023-09-21 153.6 13.6 -2.4 -2.0
VNRX 2023-09-20 159.5 14.2 -2.5 -2.0
VNRX 2023-09-19 158.0 14.0 -2.5 -2.0
VNRX 2023-09-18 174.6 15.5 -2.7 -2.3
VNRX 2023-09-15 183.6 16.3 -2.9 -2.4

VNRX Growth Metrics

    Its 3 year net cashflow from operations growth rate is now at 21.36%.
  • Its 2 year price growth rate is now at -44.15%.
  • Its year over year price growth rate is now at -25.24%.
Over the past 49 months, VNRX's revenue has gone up $200,917.

The table below shows VNRX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 0.200917 -14.50401 -31.06183
2022-06-30 0.193686 -12.56319 -30.4553
2022-03-31 0.178716 -11.69893 -28.33255
2021-12-31 0.090035 -20.85392 -26.81467
2021-09-30 0.082915 -19.17901 -23.91666
2021-06-30 0.058007 -18.80059 -21.10812

VNRX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • VNRX has a Quality Grade of D, ranking ahead of 5.68% of graded US stocks.
  • VNRX's asset turnover comes in at 0.002 -- ranking 424th of 680 Pharmaceutical Products stocks.
  • CDTX, KALA, and NVS are the stocks whose asset turnover ratios are most correlated with VNRX.

The table below shows VNRX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -4.279
2021-03-31 0.001 1 -4.727
2020-12-31 0.001 1 -5.183
2020-09-30 0.000 1 -4.958
2020-06-30 0.001 1 -5.040
2020-03-31 0.001 1 -4.625

VolitionRX Limited (VNRX) Company Bio

VolitionRX Limited, a clinical-stage life sciences company, focuses on developing blood-based diagnostic tests for detecting and diagnosing cancer and other diseases. The company is based in Singapore.

VNRX Latest News Stream

Event/Time News Detail
Loading, please wait...

VNRX Latest Social Stream

Loading social stream, please wait...

View Full VNRX Social Stream

Latest VNRX News From Around the Web

Below are the latest news stories about VOLITIONRX LTD that investors may wish to consider to help them evaluate VNRX as an investment opportunity.

Volition Hosts Key Opinion Leader Roundtable on Sepsis Management

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a Key Opinion Leader ("KOL") roundtable discussion in Athens this weekend, bringing together world-renowned experts in sepsis.

Yahoo | September 13, 2023

VolitionRx (VNRX): Review of 2Q 2023; Distribution Footprint of Nu.Q Vet Cancer Test is expanding. Prolific Schedule of Clinical Papers & Posters.

By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT Second Quarter Highlights Nu.Q Vet Product sales of the Nu. Q Vet Canine Cancer Screening Test grew 459% YOY and 15.0% sequentially (off a low base) driven primarily by sales of reference kits through IDEXX, which launched the test in the U.S. during January. Domestically, IDEXX has 20 affiliated reference laboratories in which

Yahoo | August 25, 2023

VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2023. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

Yahoo | August 14, 2023

VolitionRx Limited Schedules Second Quarter 2023 Earnings Conference Call and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, August 15 at 8.30 a.m. Eastern Time to discuss its financial and operating results for the second quarter 2023, in addition to providing a business update. Details of this event can also be found below.

Yahoo | August 9, 2023

VolitionRx Limited Announces Exercise of Over-Allotment Option by Underwriters

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that the underwriters of its previously announced underwritten public offering of its common stock have exercised their option to purchase an additional 1,950,000 shares to cover over allotments, bringing the total gross proceeds to Volition from the offering to approximately $19.0 million, before deducting underwriting commissions and other offering expenses payable by Volition. All of t

Yahoo | June 23, 2023

Read More 'VNRX' Stories Here

VNRX Price Returns

1-mo N/A
3-mo -48.53%
6-mo N/A
1-year -52.05%
3-year -78.06%
5-year -75.00%
YTD -71.19%
2022 -22.61%
2021 -19.28%
2020 -17.93%
2019 161.88%
2018 -38.44%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!